Estudo epidemiológico da Hepatite C em pessoas privadas de liberdade

Conteúdo do artigo principal

Geisa Perez Medina Gomide
Mariana dos Santos Teixeira
Guilherme Andrade Pereira
Fernanda Carolina Camargo
Beatriz Guerta Pastori
Felipe Ferreira Dias
Júlio Cesar do Carmo Ferreira
Pedro Teixeira Meireles
Nathan Castro Silva
Otilia Silva de Carvalho Neta
Vanessa Guizolfe Sales de Lima
Rejane Andrea de Paulo Cunha
Douglas Reis Abdalla
Cristina da Cunha Hueb Barata de Oliveira

Resumo

Introdução: A prevalência da hepatite C (HCV) é elevada entre os prisioneiros. Se não tratada, proporção substancial das infecções progride para cirrose, hepatocarcinoma ou insuficiência hepática. Organização Mundial de Saúde tem a meta de reduzir a incidência da infecção em 90% até 2030. Objetivo: Descrever a prevalência do anti-HCV e os aspectos sociodemográficos e clínicos, relacionados à presença do anticorpo, na população privada de liberdade. Métodos: Estudo transversal por inquérito epidemiológico, com componente exploratório, observacional, quantitativo-analítico. Foi calculada amostra aleatória simples de 233 pessoas, Intervalo de Confiança (IC) 95%, margem de erro 4% para população de 1564 prisioneiros. Foi avaliada a relação entre os aspectos sociodemográficos e clínicos com o desfecho obtido pelo teste rápido para anti-HCV por meio da medida associativa Razão de Prevalência (RP) e IC de 95% para essa estimativa. Resultados: Participaram 240 pessoas. A prevalência do anti-HCV foi de 2%, sendo que o uso de drogas injetáveis (RP 14,75; RPIC95% 2,09-104,28), ter nascido nas décadas de 1951 a 1980 (RP 9,28; RPIC95% 1,06-81,57) e ser coinfectado com o vírus da hepatite B (RP 10,75; RPIC95% 1,66-69,65) foram os aspectos que apresentaram razão de prevalência para a presença do vírus, passível de generalização para a população. Conclusão: Trata-se de população de difícil acesso, o estudo é relevante por contribuir para medidas preventivas de saúde pública no sistema prisional. Outrossim, mostra a necessidade de se implementar medidas para evitar e conter a disseminação de HCV, visando a microeliminação da hepatite C na população carcerária.

Downloads

Não há dados estatísticos.

Detalhes do artigo

Como Citar
Gomide, G. P. M., Teixeira, M. dos S., Pereira, G. A., Camargo, F. C., Pastori, B. G., Dias, F. F., Ferreira, J. C. do C., Meireles, P. T., Silva, N. C., Carvalho Neta, O. S. de, Lima, V. G. S. de, Cunha, R. A. de P., Abdalla, D. R., & Oliveira, C. da C. H. B. de. (2024). Estudo epidemiológico da Hepatite C em pessoas privadas de liberdade. ABCS Health Sciences. https://doi.org/10.7322/abcshs.2022103.1653
Seção
Artigos Originais

Referências

Akiyama MJ. Hepatitis C in the criminal justice system: opportunities for global action in the era of viral hepatitis elimination. BMC Med. 2020;18(1):208. https://doi.org/10.1186/s12916-020-01680-0

Snow KJ, Richards AH, Kinner SA. Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study. Plos One. 2017;12(7):e0180646. https://doi.org/10.1371/journal.pone.0180646

Akiyama MJ, Ross J, Rimawi F, Fox A, Jordan AO, Wiersema J, et al. Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study. Plos One. 2020;15(12):e0242623. https://doi.org/10.1371/journal.pone.0242623

AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54. https://doi.org/10.1002/hep.27950

AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infec Dis. 2018;67(10):1477-92. https://doi.org/10.1093/cid/ciy585

Puga MAM, Bandeira LM, Pompilio MA, Croda J, Rezende GR, Dorisbor LFP, et al. Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil. Plos One. 2017;12(1):e0169195. https://doi.org/10.1371/journal.pone.0169195

Queiroz IT, Couras S, Cabral D. Micro-elimination of hepatitis c in the incarcerated population: is it really possible? Arq Gastroenterol. 2021;58(3):399-401. https://doi.org/10.1590/S0004-2803.202100000-67

Araújo TME, Pinheiro DM, Souza ATS. Hepatitis C and associated risks in prisons: an integrative review. Rev Pesq Cuidado Fund Online. 2017;9(4):939-45. https://doi.org/10.9789/2175-5361.2017.v9i4.939-945

Gomide GPM, Teixeira MS, Pereira GA, Camargo FC, Pastori BG, Dias FF, et al. Experience in the management of action research on hepatitis C investigation with the prison community. Cienc Saude Coletiva. 2022;27(12):4389-96. https://doi.org/10.1590/1413-812320222712.08742022

Magri MC, Ibrahim KY, Pinto WP, França FO, Bernardo WM, Tengan FM. Prevalence of hepatitis C virus in Brazil's inmate population: a systematic review. Rev Saude Publica. 2015;49:36. https://doi.org/10.1590/S0034-8910.2015049005886

Coêlho HC. Presença dos vírus HBV e HCV e seus fatores de riscos nos presidiários masculinos da penitenciária de Ribeirão Preto. [Dissertation]. [Ribeirão Preto]: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 2008.

Gomide GPM, Melo CB, Santos VS, Salge VD, Camargo FC, Pereira GA, et al. Epidemiological survey of hepatitis C in a region considered to have high prevalence: the state of Minas Gerais, Brazil. Rev Soc Bras Med Trop. 2019;52:e20190202. https://doi.org/10.1590/0037-8682-0202-2019

Winter RJ, Holmes JA, Tj Papaluca, AJ Thompson. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14(3):497. https://doi.org/10.3390/v14030497

Gomide GPM, Molina RJ, Pereira GA, Oliveira CCHB. Early diagnosis of hepatitis C by primary health care. REFACS. 2021;9(Supl. 1):271-81. https://doi.org/10.18554/refacs.v9i0.4242

Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis. 2021;25(4):817-29. https://doi.org/10.1016/j.cld.2021.06.008

Viola L, Marciano S, Colombato L, Coelho H, Cheinquer H, Bugarin G, et al. HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America. Ann Hepatol. 2020;19(2):161-5. https://doi.org/10.1016/j.aohep.2019.09.006

Alonso M, Gutzman A, Mazin R, Pinzon CE, Reveiz L, Ghidinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health. 2015;60(7):789-98. https://doi.org/10.1007/s00038-015-0708-5

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5(12):e1192-e207. https://doi.org/10.1016/S2214-109X(17)30375-3

Boelen L, Teutsch S, Wilson DP, Dolan K, Dore GJ, Lloyd AR, et al. Per-event probability of hepatitis C infection during sharing of injecting equipment. Plos One. 2014;9(7):e100749. https://doi.org/10.1371/journal.pone.0100749

Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. BMC Public Health. 2020;20(1):1670. https://doi.org/10.1186/s12889-020-09515-6

Werling K, Hunyady B, Makara M, Nemesi K, Horváth G, Schneider F, et al. Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents. Viruses. 2022;14(2):308. https://doi.org/10.3390/v14020308

Belaunzarán-Zamudio PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, Ahmed S, Beyer C. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. Plos One. 2017;12(6):e0179931. https://doi.org/10.1371/journal.pone.0179931

Guimarães T, Granato CF, Varella D, Ferraz ML, Castle A, Kallás EG. High prevalence of hepatitis C infection in a Brazilian prison: identification of risk factors for infection. Braz J Infect Dis. 2001;5(3):111-8. https://doi.org/10.1590/s1413-86702001000300002

Gonçalves K. Life history and health situation in the prison environment of Goiás: study of the prevalence of hepatitis C in inmates [Dissertation]. [Goiânia]: Universidade Católica de Goiás, 2005.

Rosa F, Carneiro M, Duro LN, Valim ARM, Reuter CP, Burgos MS, et al. Prevalence of anti-HCV in an inmate population. Rev Assoc Med Bras. 2012;58(5):557-60. https://doi.org/10.1590/S0104-42302012000500012

Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails. Am J Public Health. 2016;106(7):1276-7. https://doi.org/10.2105/AJPH.2016.303163

Oliveira AC, Bortotti AC, Nunes NN, El Bacha IAH, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz J Infect Dis. 2014;18(5):507-11. https://doi.org/10.1016/j.bjid.2014.04.003

Busschots D, Kremer C, Bielen R, Koc OM, Heyens L, Brixko C, et al. A multicentre interventional study to assess blood-borne viral infections in Belgian prisons. BMC Infect Dis. 2021;708. https://doi.org/10.1186/s12879-021-06405-z

Mohtasham-Amiri Z, Rezvani SM, Ashoori F, Behboodi M, Toosi H, Jafari-Shakib R. Seroprevalence of Hepatitis C Virus among Prisoners in Lakan Prison, North of Iran, Is There Still a Concern? Arch Iran Med. 2021;24(10):765-70. https://doi.org/10.34172/aim.2021.113

Tejera-Pérez RJ, Iglesias-Gómez A, Oliva-Oliva A, Rodríguez-Alonso B, Alonso-Sardón M, Ledesma MS, et al. Real-life experience of hepatitis C treatment in a Spanish prison. Rev Esp Chemioter. 2022;35(3):273-8. https://doi.org/10.37201/req/001.2022